ClinicalTrials.gg
RecruitingNCT06819969CLOUDUpdated Mar 30, 2026

The Canadian Lung Outcomes in Users of Vaping Devices Study

An observational study in Small Airways Diseases, Vaping and Vaping Related Disorder, sponsored by University of British Columbia. Recruiting at 8 sites in Canada. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by University of British Columbia · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Vaping with a site in Canada — 6 open to participants now, 8 under way, 1 of them phase 3. Vaping · Canada.

Started
2025
with 1 other
Observational
3 of 13
3 open now
Registered
11th of 13
by date
Lead sponsor
1 of 13
University of British Columbia

Among the 13 studies in Vaping with a site in Canada, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 11th registered.

Vaping

404 studies on the registry are indexed under Vaping; 97 are open to participants now.

Browse Vaping studies →

Open to participants now

6 of the 13 studies in Vaping with a site in Canada are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Vaping with a site in Canada, or all of them as a file.
02

Study summary

Vaping is increasingly popular with both adolescent and adult Canadians, but the long-term health impacts remain unknown. We believe that the tools we currently have to detect lung disease in people who vape may be insufficient and propose new ways to find lung injuries that may impact them over the course of their lives. These include exercise testing, new imaging techniques, and new breathing tests that will demonstrate how vaping may harm their lungs. We will use these tools in both adolescent and adult Canadians to give Canadians who vape important information on the consequences of vaping.

Read the detailed description

Promoted as a safer method of inhaling nicotine compared to cigarettes and as smoking cessation tools, e-cigarettes have substantially grown in popularity with rates of uptake now exceeding those of cigarette smoking. In Canada, 6% of Canadians aged 15 years and older have vaped in the past 30 days. Younger Canadians appear to be the most susceptible to these habits, with 14% of those aged 15-19 years and 18% of those aged 20-24 years reporting past 30 day use. Indigenous populations are also disproportionately affected by the spread of vaping which may place them at higher risk for potential downstream respiratory complications. As Canadians increasingly reach for e-cigarettes, especially at younger ages and not just for the purposes of smoking cessation, greater clarity into the pulmonary toxicities vaping is urgently needed.

The Canadian Lung Outcomes in Users of Vaping Devices (CLOUD) Study is a pan-Canadian, multicentre, multidisciplinary, and longitudinal approach to studying vaping from cell to society. The characterization of e-cigarettes' respiratory effects remains superficial and a more comprehensive phenotyping of vaping-exposed lungs across the lifespan using novel imaging and pulmonary function techniques, dynamic exercise testing, and airway cell sequencing would significantly enhance our understanding of the potential harms. As with combustible cigarette smoking, the small airways (characterized by a diameter \<2mm) may be particularly vulnerable during vaping given their high degree of exposure to particulate matter. These regions of the lung may harbour the earliest signs of injury, ultimately setting the stage for future obstructive airways disease.

Objectives

The objective of the CLOUD Study is to characterize small airway injury in adolescent and adult Canadians who use e-cigarettes. Specifically, our goals are to:

  1. Characterize the structural and functional disruptions associated with e-cigarette use using oscillometry, multiple breath washout, chest computed tomography, hyperpolarized 129-xenon magnetic resonance imaging, cardiopulmonary exercise testing, and bronchoscopy.
  2. Determine the association between e-cigarette use and respiratory outcomes, including symptom burdens, exacerbation-like respiratory events, and school and work absences.
  3. Characterize the epigenetic and transcriptomic disruptions associated with e-cigarette use in blood, sputum, airway epithelium, and lung immune cells.

Methods Our observational, longitudinal cohort study encompasses six academic hospital centres across Canada (the University of British Columbia, the University of Alberta, McMaster University, the University of Ottawa, the University of Toronto, and the Université de Sherbrooke). Participants (n=100 ages >12 and \<19 years and n=400 ages ≥19 years) will be followed over 3 years, undergoing repeat demographic and respiratory symptom questionnaires, oscillometry, pulmonary function testing, and exercise testing. Adolescent participants will additionally undergo multiple breath washout and induced sputum collection and adult participants will undergo chest CT imaging and bronchoscopy. A substudy of adolescent and adult participants undergoing pulmonary hyperpolarized 129-xenon gas magnetic resonance imaging will also be performed. Induced sputum and bronchoscopy-derived airway epithelial and bronchoalveolar lavage samples will be sequenced for methylation and transcriptomics.

03

Conditions studied

  • Small Airways Diseases
  • Vaping
  • Vaping Related Disorder
  • Vaping Teens
  • Vaping Behavior

Browse trials for

Keywords

  • CLOUD
  • small airway injury
  • vaping
  • vape
  • e-cigarette
  • oscillometry
  • multiple breath washout
  • chest computed tomography
  • chest CT
  • hyperpolarized 129-xenon
  • MRI
  • CPET
  • bronchoscopy
  • transcriptomics
  • epigenetics
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study will enroll both adolescent (ages ≥12 and \<19 years) and adult (≥19 years) e-cigarette and non-e-cigarette users in six academic hospital centres across Canada.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adolescent arm:

  • Aged ≥12 and \<19 years old
  • Either 1) use neither combustible cigarettes nor e-cigarettes or 2) use e-cigarettes exclusively

Adult arm:

  • Aged ≥19 years old
  • Fall into one of the following categories: 1) use neither combustible cigarettes nor e-cigarettes; 2) use combustible cigarettes exclusively, never using e-cigarettes; 3) use e-cigarettes exclusively, never using combustible cigarettes; or 4) use both combustible cigarettes and e-cigarettes currently

Exclusion criteria

Exclusion Criteria:

Adolescent arm:

  • to pulmonary function testing and cardiopulmonary exercise testing
  • Have smoked combustible cannabis within the last month and/or have a combustible cannabis smoking history of >1 joint-year
  • Have smoked combustible cigarettes within the last 6 months
  • Have a physician-diagnosed chronic lung disease (such as asthma, cystic fibrosis, or bronchopulmonary dysplasia)
  • Inability to provide written

Adult arm:

  • Contraindication to pulmonary function testing and cardiopulmonary exercise testing
  • Have smoked combustible cannabis within the last month and/or have a combustible cannabis smoking history of >1 joint-year
  • Currently undergoing treatment for lung cancer
  • Inability to provide written informed consent

No limitations will be placed on the type of e-liquids used by participants; e.g., e-cigarette users of nicotine, tetrahydrocannabinol, and cannabidiol will be all enrolled.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Adults

    Canadian adults aged 19 years or older. We will be enrolling e-cigarette-only users, non-e-cigarette and non-combustible cigarette users, combustible cigarette-only users, and dual combustible cigarette-e-cigarette users.

  • Adolescents

    Canadian adolescents aged between 12 and \<19 years, inclusive. We will be enrolling e-cigarette-only users, as well as non-e-cigarette and non-combustible cigarette users.

06

What researchers measure

Primary outcomes

  1. Composite Measure of Small Airways Dysfunction

    Participants meeting at least one of the following criteria will be considered to have small airways dysfunction: For adolescent participants, these measures will include 1) a change in resistance from 5-20 Hz (R5-R20) \>upper limit of normal (ULN) on oscillometry or 2) peak oxygen consumption (VO2)\<lower limit of normal (LLN) plus a ventilatory response or minute ventilation/carbon dioxide production (VE/VCO2) nadir \>ULN. For adult participants, these measures will include 1) R5-R20 \>ULN, 2) disease probability measure functional small airways disease \>10% on chest CT, or 3) peak VO2\<84% predicted plus a VE/VCO2 nadir \>ULN. The proportion of participants meeting at least one of the criteria for small airways dysfunction at any time point will be compared between the vaping and control groups using Chi-square tests. Multivariable logistic regressions will be used to adjust for possible covariates, such as age, sex, and their interaction with vaping/smoking groups.

    Time frame: From enrollment (Baseline) to the end of study participation (36 Months).

Secondary outcomes

  1. FEV1

    Outcome measured in units of Liters (L) for all study participants.

    Time frame: 36 Months

  2. FVC

    Outcome measured in units of Liters (L) for all study participants.

    Time frame: 36 Months

  3. FEV1/FVC

    Outcome measured in units of 0-100% for all study participants.

    Time frame: 36 Months

  4. FEV3/FEV6

    Outcome measured in units of 0-100% for all study participants.

    Time frame: 36 Months

  5. Total Lung Capacity

    Outcome measured in units of Liters (L) for all study participants.

    Time frame: 36 Months

  6. Diffusion Capacity

    Outcome measured in units of mL/min/mmHg for all study participants.

    Time frame: 36 Months

  7. Small Airways Resistance R5-R20

    Outcome measured in units of kPa/l/s for all study participants.

    Time frame: 36 Months

  8. Ventilation Defect Percent

    Outcomes measured in units of 0-100% for study participants in the following sites: St. Paul's Hospital (University of British Columbia), BC Children's Hospital (University of British Columbia), the Hospital for Sick Children (University of Toronto), St. Joseph's Healthcare Hamilton (McMaster University).

    Time frame: 36 Months

  9. RBC to Membrane Ratio

    Outcomes measured in units of a ratio for study participants in the following sites: St. Paul's Hospital (University of British Columbia), BC Children's Hospital (University of British Columbia), the Hospital for Sick Children (University of Toronto), St. Joseph's Healthcare Hamilton (McMaster University).

    Time frame: 36 Months

  10. Membrane to Gas Ratio

    Outcomes measured in units of a ratio for study participants in the following sites: St. Paul's Hospital (University of British Columbia), BC Children's Hospital (University of British Columbia), the Hospital for Sick Children (University of Toronto), St. Joseph's Healthcare Hamilton (McMaster University).

    Time frame: 36 Months

  11. Apparent Diffusion Coefficient

    Outcomes measured in units of cm2/s for study participants in the following sites: St. Paul's Hospital (University of British Columbia), BC Children's Hospital (University of British Columbia), the Hospital for Sick Children (University of Toronto), St. Joseph's Healthcare Hamilton (McMaster University).

    Time frame: 36 Months

  12. Peak VO2 %predicted

    Outcomes measured in units of 0-100% for all study participants.

    Time frame: 36 Months

  13. VE/VCO2 nadir

    Outcomes measured in units of a ratio for all study participants.

    Time frame: 36 Months

  14. Epigenetic Age (Blood Methylation)

    Outcomes measured in units of age acceleration residual for all study participants.

    Time frame: 36 Months

  15. Differentially Methylated Genes (Blood Methylation)

    Outcomes measured in units of beta-values for all study participants.

    Time frame: 36 Months

  16. Differentially Expressed Genes (Blood Transcriptome)

    Outcomes measured in units of transcripts per million for all study participants.

    Time frame: 36 Months

  17. Epigenetic Age (Induced Sputum Methylation)

    Outcomes measured in units of age acceleration residual for adolescent study participants in the following sites: BC Children's Hospital (University of British Columbia), the Hospital for Sick Children (University of Toronto), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke).

    Time frame: 36 Months

  18. Differentially Methylated Genes (Induced Sputum Methylation)

    Outcomes measured in units of beta-values for adolescent study participants in the following sites: BC Children's Hospital (University of British Columbia), the Hospital for Sick Children (University of Toronto), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke).

    Time frame: 36 Months

  19. Differentially Expressed Genes (Induced Sputum Transcriptome)

    Outcomes measured in units of transcripts per million for adolescent study participants in the following sites: BC Children's Hospital (University of British Columbia), the Hospital for Sick Children (University of Toronto), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke).

    Time frame: 36 Months

  20. Epigenetic Age (Bronchial Epithelial Cell and Bronchoalveolar Lavage Methylation)

    Outcomes measured in units of age acceleration residual for adult study participants in the following sites: St. Paul's Hospital (University of British Columbia), St. Joseph's Healthcare Hamilton (McMaster University), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke).

    Time frame: 36 Months

  21. Differentially Methylated Genes (Bronchial Epithelial Cell and Bronchoalveolar Lavage Methylation)

    Outcomes measured in units of beta-values for adult study participants in the following sites: St. Paul's Hospital (University of British Columbia), St. Joseph's Healthcare Hamilton (McMaster University), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke).

    Time frame: 36 Months

  22. Differentially Expressed Genes (Bronchial Epithelial Cell and Bronchoalveolar Lavage Transcriptome)

    Outcomes measured in units of transcripts per million for adult study participants in the following sites: St. Paul's Hospital (University of British Columbia), St. Joseph's Healthcare Hamilton (McMaster University), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke).

    Time frame: 36 Months

  23. Lung Clearance Index

    Outcomes measured in counts for adolescent study participants in the following sites: BC Children's Hospital (University of British Columbia), the Hospital for Sick Children (University of Toronto).

    Time frame: 36 Months

  24. DPM fSAD

    Outcomes measured in units of 0-100% for adult study participants in the following sites: St. Paul's Hospital (University of British Columbia), St. Joseph's Healthcare Hamilton (McMaster University), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke), Clinical Sciences Building (University of Alberta), Ottawa Hospital General Campus (University of Ottawa).

    Time frame: 36 Months

  25. LAA856

    Outcomes measured in units of 0-100% for adult study participants in the following sites: St. Paul's Hospital (University of British Columbia), St. Joseph's Healthcare Hamilton (McMaster University), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke), Clinical Sciences Building (University of Alberta), Ottawa Hospital General Campus (University of Ottawa).

    Time frame: 36 Months

  26. LAA950 (Quantitative Emphysema)

    Outcomes measured in units of 0-100% for adult study participants in the following sites: St. Paul's Hospital (University of British Columbia), St. Joseph's Healthcare Hamilton (McMaster University), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke), Clinical Sciences Building (University of Alberta), Ottawa Hospital General Campus (University of Ottawa).

    Time frame: 36 Months

  27. Qualitative Emphysema

    Outcomes measured in units of 0-100% for adult study participants in the following sites: St. Paul's Hospital (University of British Columbia), St. Joseph's Healthcare Hamilton (McMaster University), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke), Clinical Sciences Building (University of Alberta), Ottawa Hospital General Campus (University of Ottawa).

    Time frame: 36 Months

  28. Pulmonary Vascular Volume

    Outcomes measured in units of milliliters (mL) for adult study participants in the following sites: St. Paul's Hospital (University of British Columbia), St. Joseph's Healthcare Hamilton (McMaster University), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke), Clinical Sciences Building (University of Alberta), Ottawa Hospital General Campus (University of Ottawa).

    Time frame: 36 Months

  29. Mucus Score

    Outcomes measured in counts for adult study participants in the following sites: St. Paul's Hospital (University of British Columbia), St. Joseph's Healthcare Hamilton (McMaster University), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke), Clinical Sciences Building (University of Alberta), Ottawa Hospital General Campus (University of Ottawa).

    Time frame: 36 Months

  30. Total Airway Counts

    Outcomes measured in counts for adult study participants in the following sites: St. Paul's Hospital (University of British Columbia), St. Joseph's Healthcare Hamilton (McMaster University), Centre Hospitalier Universitaire de Sherbrooke (Universite de Sherbrooke), Clinical Sciences Building (University of Alberta), Ottawa Hospital General Campus (University of Ottawa).

    Time frame: 36 Months

07

Study locations

5 of 8 sites recruiting
  • University of Alberta (Clinical Sciences Building)
    Edmonton, Alberta T6G 2B7, Canada
    Recruiting
    • Michael Stickland · Contactmks2@ualberta.ca · (780) 492-1657
    • Desi Fuhr · Contactfuhr@ualberta.ca
    • Michael Stickland · Sub investigator
    • Joanna Maclean · Sub investigator
  • BC Cancer Agency
    Vancouver, British Columbia V5Z 4E6, Canada
    Recruiting
  • BC Children's Hospital Research Institute
    Vancouver, British Columbia V6H 3N1, Canada
    Recruiting
  • St. Paul's Hospital
    Vancouver, British Columbia V6Z 1Y6, Canada
    Recruiting
    • Janice Leung · Contactjanice.leung@hli.ubc.ca · 604-836-0423
    • Paloma Burns · Contactpburns@providencehealth.bc.ca · 604-442-7021
    • Janice Leung · Principal investigator
    • Don Sin · Sub investigator
    • Rachel Eddy · Sub investigator
    • Jonathon Leipsic · Sub investigator
  • McMaster University (Research Institute of St. Joe's Hamilton)
    Hamilton, Ontario L8N 4A6, Canada
    Not yet recruiting
    • Terence Ho · Contacthot4@mcmaster.ca · Unavailable
    • Sarah Svenningsen · Contactsvennins@mcmaster.ca · 905-522-1155
    • Terence Ho · Sub investigator
    • Sarah Svenningsen · Sub investigator
  • University of Ottawa (The Ottawa Hospital General Campus)
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
  • University of Toronto (The Hospital for Sick Children)
    Toronto, Ontario M5G 1E8, Canada
    Not yet recruiting
  • Université de Sherbrooke
    Sherbrooke, Quebec J1N 3C6, Canada
    Not yet recruiting
08

References and documents

Publications

  • Burns P, Eddy RL, Li X, Yang J, Dhillon SS, Couillard S, Stickland MK, Guenette J, Svenningsen S, Tulloch T, Samji H, Meza R, Struik LL, Aaron S, Ho T, Lam S, Leipsic J, Maclean J, Afshar T, Moraes TJ, Zanette B, Santyr G, Counil FP, Hernandez Cordero AI, Matano S, de Arruda Maluf G, Leung C, Feng C, Bal L, Dhaliwal H, Mumuni A, Lui C, Drew H, Sin DD, Rayment JH, Leung JM. The Canadian Lung Outcomes in Users of Vaping Devices (CLOUD) Study: protocol for a prospective, observational cohort study. BMJ Open. 2025 Mar 6;15(3):e100568. doi: 10.1136/bmjopen-2025-100568. PubMed 40050062 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2029, 53 months after the start.

Of 32 observational studies under Vaping, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 46. This study's planned 53 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Feb 11, 2025
StartActual
Jul 25, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06819969
Responsible party
Janice Leung (Assistant Professor, Department of Medicine, University of British Columbia, Principal Investigator, Centre for Heart Lung Innovation, St. Paul's Hospital, Respirologist, St. Paul's Hospital, University of British Columbia) — Principal investigator
First posted
Feb 11, 2025
Start date
Jul 25, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Mar 30, 2026

Study contacts

Janice Leung, MD
Contact
janice.leung@hli.ubc.ca
604-836-0423
Paloma Burns, MSc
Contact
pburns@providencehealth.bc.ca
604-442-7021
Janice Leung, MD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion